TriangleBalstilimab (NCT06843434)
Balstilimab trial for Microsatellite Stable Rectal Carcinoma (NCT06843434). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated stage two or three rectal adenocarcinoma that is mismatch-repair-proficient or microsatellite-stable. Distant spread and recurrent rectal cancer exclude participation.
The idea: botensilimab targets CTLA4 and balstilimab targets PD1, two immune brakes. Researchers assess the combination before local treatment. MRI and endoscopy measure partial, near-complete, or complete clinical response. The study also examines safety. The public record does not specify doses, schedules, or when standard chemotherapy may be added.
This phase 2 study plans 40 patients. Andrea Cercek leads at MSK, New York; seven US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.